Immix Biopharma Inc. Financials
IMMX
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 ~1.6:1 split | DEC 2023 | DEC 2022 ~3.8:1 split | DEC 2021 |
|---|---|---|---|---|---|
| General & Administrative | $14 | $11 | $7 | $4 | $1 |
| Research & Development | $16 | $11 | $9 | $4 | $0 |
| Total Operating Expenses | $30 | $23 | $16 | $8 | $1 |
| Operating Income | -$30 | -$23 | -$16 | -$8 | -$1 |
| Non-Operating | |||||
| Net Interest Expense | $1 | $1 | $1 | -$0 | -$0 |
| Other Non-Operating Income (Expense) | $0 | $0 | $0 | $0 | -$23 |
| EBT (Earnings Before Tax) | -$29 | -$22 | -$16 | -$8 | -$24 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Minority Interest | – | -$0 | -$0 | – | – |
| Net Income | |||||
| Net Income | -$29 | -$22 | -$15 | -$8 | -$24 |
| EPS (Basic) | -$0.89 | -$0.76 | -$0.89 | -$0.59 | -$6.64 |
| EPS (Diluted) | -$0.89 | -$0.76 | -$0.89 | -$0.59 | -$6.64 |
| Weighted Avg Shares (Basic) | 33.0M | 28.3M | 17.3M | 13.9M | 3.7M |
| Weighted Avg Shares (Diluted) | 33.0M | 28.3M | 17.3M | 13.9M | 3.7M |
| Shares Outstanding | 33.0M | 28.3M | 17.3M | 13.9M | 3.7M |
Immix Biopharma (IMMX) financials: revenue, profit and margins
Immix Biopharma (IMMX) generated about n/a in revenue and -$46 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Immix Biopharma profitable?+
Immix Biopharma reported about -$46 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 30 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with IMMX
Held by ETFs
IMMX is in 11 US ETFs. The largest of them, with IMMX's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.16%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.07%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.04%of the fund
iShares Micro-Cap ETFIWC0.12%of the fund
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC0.06%of the fund
Spot a number that looks wrong? Check it in IMMX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMMX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.